Skip Navigation


European Heart Journal Advance Access originally published online on October 24, 2005
European Heart Journal 2005 26(23):2596-2599; doi:10.1093/eurheartj/ehi615
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
26/23/2596    most recent
ehi615v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Keuper, W.
Right arrow Articles by Verheugt, F. W.A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Keuper, W.
Right arrow Articles by Verheugt, F. W.A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Hotline Sessions of the 27th European Congress of Cardiology

Wessel Keuper and Freek W.A. Verheugt*

Radboud University Nijmegen Medical Centre, Heartcentre, 670 Cardiology, PO Box 9101, 6500 HB Nijmegen, The Netherlands

Received 29 September 2005; accepted 6 October 2005; online publish-ahead-of-print 24 October 2005.

* Corresponding author. Tel: +31 24 3614533; fax: +31 24 3540537. E-mail address: f.verheugt@cardio.umcn.nl

The first 150 words of the full text of this article appear below.

This year's Congress of the European Society of Cardiology was held in Stockholm, Sweden from the 3rd to the 7th of September 2005. Summaries of the preliminary results of 12 of the 14 studies presented at the three Hotline Sessions are reported here. The CIBIS-III and BASKET trials have been published in Circulation 2005;112:2426–2435 and Lancet 2005;366:921–929, respectively. Data reported in this summary have been collected from press releases and presentations of the speakers.

During the first Hotline Session, three trials on heart failure were presented. Prof. Marco Metra from Brescia, Italy presented the ESSENTIAL study. In this randomized placebo-controlled trial, the effect of long-term treatment with low-dose oral enoximone (25–50 mg three times daily), a phosphodiesterase III inhibitor, in patients with advanced heart failure was studied. It was hypothesized that enoximone could reduce the co-primary endpoints time to cardiovascular (CV) hospitalization or all-cause mortality . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?